JBIO · Jade Biosciences, Inc.
$21.62
+0.39 (+1.84%)
At close · Aug 21
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$1.43B
Shares
63.60M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Tom Frohlich | Chief Executive Officer, President and Director | $9,799,759 |
| Andrew King | President, Research and Development | $4,541,804 |
| Bradford Dahms | Chief Financial Officer | $4,131,991 |
| Timothy P. Noyes | Former Chief Executive Officer | $1,814,483 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Timothy P. Noyes | Former Chief Executive Officer | $3,391,536 |
| Tom Frohlich | Chief Executive Officer, President and Director | $1,364,396 |
| Andrew King | President, Research and Development | $751,605 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Timothy P. Noyes | Chief Executive Officer | $5,305,461 |
| Benjamin T. Dake | President, Chief Operating Officer and Secretary | $2,878,821 |
| George A. Eldridge | Chief Financial Officer | $1,690,904 |
| Hunter Gillies | M.B.Ch.B. Chief Medical Officer | $1,632,478 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Benjamin T. Dake | President, Chief Operating Officer and Secretary | $502,119 |
| Hunter Gillies | M.B.Ch.B. Chief Medical Officer | $423,441 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mark Eisner, M.D., M.P.H. | Class I director | Appointed | 2026-06-26 |
| Andrew King, BVMS, Ph.D. | President, Research & Development | Appointed | 2026-04-22 |
| Bradford Dahms | Chief Financial Officer and Treasurer | Appointed | 2025-07-01 |
| Maha Katabi, Ph.D. | board of directors | Resigned | 2024-10-10 |
| Habib J. Dable | member of the Board | Appointed | 2023-07-11 |
| Donald J. Santel | member of the Board | Appointed | 2023-01-23 |
| Joshua Resnick, M.D. | member of the Audit Committee | Resigned | 2021-07-19 |
| Maha Katabi, Ph.D. | chair of the Audit Committee | Resigned | 2021-07-19 |
| Allison Dorval | chair of the Audit Committee | Appointed | 2021-07-19 |
| Allison Dorval | member of the Board | Appointed | 2021-07-19 |
Key facts
CIK
1798749
CUSIP
008064206
13F (30d)
148 filings
147 filers
Visit website
Investor relations